Evaluation of the Therapeutic Efficacy of Nutraceuticals in Dissolving Nephrolites in Felines (Felis catus, Linnaeus, 1758)
feline, renal disease, nutraceuticals, clinical
Nephrolithiasis is a condition frequently seen in the feline species, with the one without chronic kidney disease, constituting the major cause of ureteral obstruction as well as progressive lesions to the renal parenchyma. Such nephrolites can form as a result of several factors that result in the precipitation of lithogenic ions. It is known that about 90% of nephrolites are composed of calcium oxalate, and that they are not capable of dissolution and that their incidence has increased substantially in recent years, together with recurrence. It is not yet known for sure, what is the correlation between nephrolithiasis and chronic kidney disease (CKD); however, the presence of one may be a predisposing factor for the development of the other and the early diagnosis of both is of paramount importance in therapeutic management. There are functional foods, known as nutraceuticals, that provide health benefits and among these, we can mention polyunsaturated fatty acids, proteins, peptides, amino acids / keto acids, minerals and vitamins. Due to these benefits and the prevalence of nephrolithiasis in the feline species, the present study will aim to evaluate the therapeutic efficacy of the combination of some of these nutraceuticals (eicosapentaenoic acid - EPA; docosahexaenoic acid - DHA; resveratrol; chelated magnesium and menaquinone) in the dissolution of these nephrolites in felines.